Curosurf, 80 mg/ml 1.5 ml

Respiratory distress syndrome (hyaline membrane disease) in preterm infants weighing more than 700 g.

Indications

Respiratory distress syndrome (hyaline membrane disease) in premature newborns weighing more than 700 g.

Pharmacological effect

Kurosurf has a surfactant-like effect.

Special instructions

Before starting treatment with Curosurf, it is necessary to correct acidosis, hypotension, anemia, hypoglycemia and hypothermia.

In case of reflux of the drug, the administration should be suspended and, if necessary, the peak inspiratory pressure on the ventilator should be increased to the level necessary to clear the endotracheal tube.

In the case of blockage of the endotracheal tube due to the accumulation of mucus in children, ventilation may noticeably deteriorate during the administration of the drug or immediately after its administration, which happens if there is pulmonary secretion in the child before the administration of the drug. Suctioning off mucus before administering the drug may reduce the likelihood of endotracheal tube obstruction. If the obstruction cannot be removed, the endotracheal tube should be replaced immediately.

Aspiration of tracheobronchial secretions is not recommended for at least 6 hours after drug administration, except under life-threatening conditions.

In the event of bradycardia, arterial hypotension and a decrease in blood oxygen saturation, the administration of the drug must be suspended and the necessary measures must be taken to normalize heart rate, after which treatment can be continued.
Children born after a long period without water (more than 3 weeks) may respond poorly to replacement therapy with Curosurf, which may be due to pulmonary hypoplasia.

Administration of the drug can be expected to reduce the severity of RDS or the risk of its occurrence, but the therapy cannot be expected to completely eliminate the mortality and morbidity associated with preterm birth, since premature babies may be subject to other complications due to their immaturity.

Active ingredient

Poractant alpha

Composition

1 ml contains poractant alpha (phospholipid fraction isolated from pig lungs) 80 mg (composition per 1 ml suspension: phospholipid fraction isolated from pig lungs – 80 mg/ml, equivalent to approximately 74 mg/ml total phospholipid concentration and 0.9 mg low molecular weight hydrophobic proteins).

Contraindications

Hypersensitivity.

Side Effects

Pulmonary hemorrhage (especially with pronounced signs of lung immaturity).

Overdose

To date, no overdose phenomena have been observed with the use of the drug Kurosurf.

However, in case of overdose and only in the presence of clear clinical manifestations (from breathing, ventilation or oxygenation), the maximum possible aspiration of suspended contents from the lungs and therapy aimed at maintaining water and electrolyte balance should be carried out.

Storage conditions

In a dark place, at a temperature of 2-8 °C.

Manufacturer

Chiesi Pharmaceuticals S.p.A., Italy